SPACInsider Logo
The Latest SPAC News and Rumors: September 21, 2022
by Marlena Haddad on 2022-09-21 at 11:35am

 


Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. 

Latest SPAC News:  Cano Health buys Doctor’s Medical Center for $300M, Ouster lays off 10% of staff, and Coeptis enters license agreement with University of Pittsburgh 


Cano Health buys Doctor’s Medical Center for $300M to cement its primary care business in Florida

Miami-based Cano Health announced today the acquisition of fellow primary care provider Doctor’s Medical Center in a bid to grow its Medicare, Medicaid and Affordable Care Act (ACA) exchange memberships in South Florida.

The deal closed July 2 and ran Cano Health $300 million, $250 million of which the company said was financed by new debt.

Cano Health—which just recently joined the public markets through a $4.4 billion special purpose acquisition company merger—runs value-based primary care centers and provides support to other primary care practices treating senior patients.

READ

Ouster lays off 10% of staff 

Ouster (NYSE:OUST) announced that it is reducing its headcount by approximately 10%, reducing spending across the business by over 15% and suspending sales of common stock through at-the-market. The changes are part of the company’s comprehensive cost reduction initiative.

As of December 2021, Ouster employed approximately 217 people on a full-time basis in the U.S. and 61 people full-time internationally, for a total of 278 employees. Ousters cuts could affect around 28 employees in the company.

Ouster went public on the NYSE in March 2021 after it completed its business combination with Colonnade Acquisition Corp., a SPAC.

READ

Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a “Multi-Antigen” CAR T Technology

Coeptis Therapeutics, Inc. (OTC PINK: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive license agreement with the University of Pittsburgh for the rights to a chimeric antigen receptor T cell (CAR T) technology – SNAP-CAR – designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including breast and ovarian cancer. Completion of the exclusive license agreement for SNAP-CAR follows Coeptis’ entry into an option agreement with the University of Pittsburgh announced in May 2022.

Bull Horn (NASDAQ:BHSE) entered into a definitive agreement to combine with biopharmaceutical company Coeptis in April.

READ

 

Recent Posts
by Marlena Haddad on 2023-01-30 at 1:22pm

Armada I (NASDAQ:AACI) announced this afternoon that it has once again postponed its extension vote. The SPAC initially planned to hold its special meeting on January 20, but postponed it to January 30, and will now be pushing it back until tomorrow, January 31. Armada has also extended the deadline for holders to submit their public...

by Nicholas Alan Clayton on 2023-01-30 at 12:07am

Prime Impact I (NYSE:PIAI) has entered into a definitive agreement to combine with auto insurance firm Cheche at an enterprise value of $841 million, or about 2.3x its 2022 revenue. Beijing-based Cheche provides a digital insurance platform for car owners in China with about 34 million vehicles covered. The combined company is expected to trade...

by Marlena Haddad on 2023-01-30 at 11:42am

  Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.  Latest SPAC News: Hambro Perks eyes merger with Biotech Istesso, Rocket Lab launches first vehicle from U.S. soil, and Alliance Entertainment signs licensing agreement with The Walt Disney Company Hambro Perks SPAC Eyes Merger With Biotech...

by Marlena Haddad on 2023-01-30 at 10:15am

Pono Capital Corp. (NASDAQ:PONO) disclosed in an 8-K filing this morning that its shareholders approved its combination with air mobility company AERWINS at a special meeting held on Friday, January 27. Holders of 12,412,861 common shares were present at the meeting and the deal was approved with 11,218,712 shares in favor of the transaction. The filing did not...

by Nicholas Alan Clayton on 2023-01-30 at 9:07am

European Biotech (NASDAQ:EBAC) announced in an 8-K this morning that it has increased its PIPE by $7.8 million and added $7 million to the convertible loans attached to the combination with biotech firm Oculis. The new PIPE cash comes at $10 per share and joins $63.3 million in existing PIPE financing for a total of...

Privacy Policy|Terms Of Use
Copyright © 2022 SPACInsider, Inc. All Rights Reserved